Skip to main content

Advertisement

Figure 5 | BMC Cancer

Figure 5

From: Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers

Figure 5

Validation of the prognostic performance of RRM2 for ER-negative breast cancers. The HR of OS and PFS for various expression levels of RRM2, ki-67, HER2, lymphonode involvement, distant metastasis and uPA were determined by Cox proportional analysis. The OS and PFS results are shown in (A) and (B). The prognostic performance of RRM2 protein was verified for the ZJU set and is shown in (C).

Back to article page